A detailed history of Dmg Group, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Dmg Group, LLC holds 12,366 shares of NVO stock, worth $1.26 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares
12,366
Previous 12,552 1.48%
Holding current value
$1.26 Million
Previous $1.79 Million 17.81%
% of portfolio
1.22%
Previous 1.54%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$119.07 - $145.42 $22,147 - $27,048
-186 Reduced 1.48%
12,366 $1.47 Million
Q2 2024

Jul 16, 2024

SELL
$122.71 - $146.91 $104,303 - $124,873
-850 Reduced 6.34%
12,552 $1.79 Million
Q1 2024

Apr 19, 2024

BUY
$102.11 - $135.92 $97,106 - $129,259
951 Added 7.64%
13,402 $1.72 Million
Q4 2023

Jan 10, 2024

SELL
$87.78 - $105.45 $236,215 - $283,765
-2,691 Reduced 17.77%
12,451 $1.29 Million
Q3 2023

Oct 26, 2023

BUY
$90.94 - $199.54 $721,608 - $1.58 Million
7,935 Added 110.1%
15,142 $1.38 Million
Q2 2023

Jul 13, 2023

SELL
$155.98 - $172.65 $144,905 - $160,391
-929 Reduced 11.42%
7,207 $1.17 Million
Q1 2023

Apr 24, 2023

SELL
$132.34 - $159.14 $35,070 - $42,172
-265 Reduced 3.15%
8,136 $1.3 Million
Q4 2022

Feb 06, 2023

SELL
$102.55 - $135.33 $2,358 - $3,112
-23 Reduced 0.27%
8,401 $1.15 Million
Q3 2022

Oct 27, 2022

SELL
$95.28 - $116.93 $16,102 - $19,761
-169 Reduced 1.97%
8,424 $864,000
Q2 2022

Aug 09, 2022

SELL
$103.24 - $121.81 $16,311 - $19,245
-158 Reduced 1.81%
8,593 $959,000
Q1 2022

Apr 25, 2022

SELL
$93.1 - $112.54 $479,185 - $579,243
-5,147 Reduced 37.03%
8,751 $969,000
Q4 2021

Jan 31, 2022

BUY
$95.88 - $117.08 $1.33 Million - $1.63 Million
13,898 New
13,898 $1.33 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $230B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Dmg Group, LLC Portfolio

Follow Dmg Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dmg Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dmg Group, LLC with notifications on news.